Patient Genotyping Could Make Critical Difference in Treating Alzheimer’s

New research on Alzheimer’s disease reveals strong evidence that clinical trials on drugs that appeared not to benefit patients with the disease should now be reanalyzed in light of discoveries about a human-specific gene that divides the population into a one-to-three ratio. “For Alzheimer’s, if we can treat 25 percent of patients, that is 1.5 million people,” says Kinga Szigeti, MD, PhD, associate professor of neurology and director of UB’s Alzheimer’s Disease and Memory Disorders Center. “That would be a major advance.”